Indivior UK Limited

Chronos Therapeutics Limited

Glaxo Group Limited

Susanna Cremonesi

Fabrizio Micheli

Luca Tarsi

Teresa Semeraro

Barbara Bertani

Tim Luker

Romano Di Fabio

Karl Richard Gibson

Colin Philip Leslie

Alessandra Pasquarello

Stefano Fontana

Alfonso Pozzan

Luca Raveglia

Timothy Jon Luker

Teresa Semerano

Riccardo Zanaletti

Colin Leslie

There is provided a compound of formula (I), wherein Lto L', Rto R, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Dopamine Dreceptor antagonist compounds

The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Substituted 3,6-diazabicyclo[3.2.0]heptanes

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine Dreceptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions. 

Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators

Dopamine D3 receptor antagonists

Dopamine D3 receptor antagonist compounds

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R, R, R, R, R, R, R, R, R, R, m, n, A, L and B are as defined herein. 

N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R, R, R, R, R, R, R, R, Q, X, Y, Z, A, L, B, m, n and p are as defined herein. 

Spirocyclic derivatives

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein

[object Object]

Growing community of inventors

Verona, Italy

Susanna Cremonesi